Facilitating Access to Approved Medication
Get Access To Mirvetuximab Soravtansine-GYNX Injection
Mirvetuximab soravtansine-gynx injection
- API: mirvetuximab soravtansine-gynx
- Trade Name: On Request
- Packaging: injection
- Strength: Injection: 100 mg/20 mL (5 mg/mL) in a single-dose vial.
What is mirvetuximab soravtansine-gynx injection used for?
mirvetuximab soravtansine-gynx is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.
Mirvetuximab soravtansine was approved for medical use in the United States in November 2022.
Note: (For Prescribing Information Approved Drugs, see)
- The Food and Drug Administration (FDA), USA.
- The European Medicines Agency (EMA).
All Trademarks and Brands that appear on website belong to their respective owners does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. mirvetuximab soravtansine-gynx injection is a pharmaceutical drug To access this medicine, a prescription of your treating doctor is necessary.. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.